: iStockAnalyst.com Symbols Feed

FDA Calendar Updates: Botox Rival Approved

Fri, 01 May 2009 17:57:59 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars.The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sB (...)[More...]

More Cash, Less Debt = Stock Market Gains?

Thu, 23 Apr 2009 13:41:32 GMT

Today there were a couple of posts about how tech stocks are currently especially attractive because they hold plenty of cash and tend to have little debt. Paul Kedrosky initially caught my eye with his post "Tech Cash is King" which in turn pointed me to a story on Bloomberg by Eric Martin. I ran a screen tonight that looked at both cash and debt. Specifically, I screened for a Price-to-Cash ratio under three, a Debt-to-Equity ratio under three and a Market Cap greater than $2.5 million. Based on these criteria, I obtained a list of 136 stocks. Judging from our list, it is absolutely true that many tech stocks do seem to have lots of cash and little debt. What also became apparent as I went through the list is that there[More...]

Updated FDA, Clinical Trial Calendars: CTIC, DNDN, MRX, JNJ, MEDX

Tue, 14 Apr 2009 16:37:16 GMT

Below is a summary of updates to the BioMedReports.com database of 241 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 115 entries through 4/14/09. The FDA Calendar includes the following information: company name, ticker, deci (...)[More...]

Midday Dividend Scan: Commercial Metals - 12 Cents; CTS - $0.03; Heinz - 41.5 cents; Medicis - $0.04; Staples - $0.0825

Wed, 11 Mar 2009 18:21:00 GMT

Midday Dividend Scan: Commercial Metals - 12 Cents; CTS - $0.03; Heinz - 41.5 cents; Medicis - $0.04; Staples - $0.0825[More...]

Midday Dividend Scan: Commercial Metals - 12 Cents; CTS - $0.03; Heinz - 41.5 cents; Medicis - $0.04; Staples - $0.0825

Wed, 11 Mar 2009 18:21:00 GMT

Midday Dividend Scan: Commercial Metals - 12 Cents; CTS - $0.03; Heinz - 41.5 cents; Medicis - $0.04; Staples - $0.0825[More...]

Medicis (NYSE:MRX): Downgraded To Sell..er..Hold at Natixis Bleichroeder

Thu, 05 Feb 2009 14:19:00 GMT

Natixis Bleichroeder is out with a pretty nasty downgrade on Medicis (NYSE:MRX) taking their rating to Hold from Buy noting the entire market seems to be against Medicis and it’s fairly easy to see why -- if they lose Solodyn to generics, they would likely start losing money. And yesterday’s news that the FDA had approved Impax’s generic the day before sent the stock into a nosedive. There is almost a universal view that the next wave of generics will be right behind and it will render Impax’s inability to launch because of the settlement with Medicis moot. And with this headwind it is hard to see the stock outperforming from here. But a large unanswered question is why only Impax? They were the only generic not sued and therefore there is no ambiguity that there would[More...]

MicuRx Pharma Picks Next-Gen MRSA Antibiotic Candidate

Tue, 19 Aug 2008 18:17:00 GMT

MicuRx Pharmaceuticals, Inc., a privately held company based in Union City, CA and Shanghai, named MRX-I as the company’s first preclinical development candidate. MicuRX is developing next-generation antibiotics aimed at multi-drug resistant gram-positive[More...]

NASDAQ Technical Picture - Narrow Range Inside Bar

Fri, 09 May 2008 06:49:38 GMT

Not much to say about today's session, except snooze fest. We carved out a NRIB in the lower half of yesterday's WRB. The 15 minute chart sums it up well, a chop[More...]

Daily Options Report - Jan 16 2008 10:50AM

Wed, 16 Jan 2008 14:44:43 GMT

Today’s tickers: VIX, BEAS, RF, XLB, C, XLF, HBC, MRX, SGP, AAPL, EMC VIX – Wilting investor sentiment on back of Citi’s killjoy writeoff and soft retail sales numbers made a dent in the Dow – down 280 points heading into the close. In bygone days, we might have expected a sharp move higher in the Volatility Index, which being tied to the S&P, tends to couple inversely with movements in that index. Surprisingly, the index read just 1.35% higher this afternoon at 23.21, having failed to register a close above 25 in a full week. This would seem to corroborate that even as the economic picture sours, it continues to gain clarity, cooling the volatility outlook considerably. With January...[More...]

Nightly Business Report - Mar 21 2009 5:53AM

Thu, 19 Mar 2009 09:48:00 GMT

SUSIE GHARIB, NIGHTLY BUSINESS REPORT ANCHOR: House Democrats go all out to get the AIG bonus money back.
DARREN GERSH, NIGHTLY BUSINESS REPORT ANCHOR: And the Fed`s bold move to buy up billions in mortgage-backed securities had phones ringing off the hook at mortgage lenders today.
This is NIGHTLY BUSINESS REPORT for Thursday, March 19.

: iStockAnalyst.com Symbols Feed

FDA Calendar Updates: Botox Rival Approved

More Cash, Less Debt = Stock Market Gains?

Updated FDA, Clinical Trial Calendars: CTIC, DNDN, MRX, JNJ, MEDX

Midday Dividend Scan: Commercial Metals - 12 Cents; CTS - $0.03; Heinz - 41.5 cents; Medicis - $0.04; Staples - $0.0825

Midday Dividend Scan: Commercial Metals - 12 Cents; CTS - $0.03; Heinz - 41.5 cents; Medicis - $0.04; Staples - $0.0825

Medicis (NYSE:MRX): Downgraded To Sell..er..Hold at Natixis Bleichroeder

MicuRx Pharma Picks Next-Gen MRSA Antibiotic Candidate

NASDAQ Technical Picture - Narrow Range Inside Bar

Daily Options Report - Jan 16 2008 10:50AM

Nightly Business Report - Mar 21 2009 5:53AM

Midday Dividend Scan: Commercial Metals - Twelve Cents; CTS - $0.03; Heinz - 41.5 cents; Medicis - $0.04; Staples - $0.0825

Botox Still Hot Despite Cool Economy

Movers: Goldman Sachs, Citigroup, AIG, Sunpower, Medicis

RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on MRX, RPM, BKE, NMR, BLL and SSL

Morning Watch for Wednesday: Sunwin International Neutraceuticals - August 19, 2009

Medicis Reports Second Quarter 2009 Financial Results

Medicis Announces Second Quarter 2009 Conference Call and Webcast

Medicis and Revance Announce Agreement for Development of Next-Gen Neurotoxin

Medicis Announces Approval of New Strengths of SOLODYN(R)

Health Canada Issues LIPOSONIX(TM) System Medical Device License

Medicis Begins Shipping Dysport(TM) for Glabellar Lines

Medicis to Present At Jefferies Healthcare Conference

Medicis Declares Cash Dividend

Form 4 MEDICIS PHARMACEUTICAL For: Nov 25 Filed by: PIETRANGELO MICHAEL (10K)

Form 4 SHACKELFORD LOTTIE H For: Aug 31 (10K)

Form 4 Hanson Jason David For: Jul 07 (10K)

Form 4 MEDICIS PHARMACEUTICAL For: May 28 Filed by: DAVIDSON SPENCER (10K)

Form 4 KNIGHT PETER S For: May 19 (10K)

Form 4 SCHEIN PHILIP S For: May 19 (10K)

Form 4 DIAMOND STUART For: May 19 (10K)

Form 4 DAVIDSON SPENCER For: May 19 (10K)

Form 4 SHACKELFORD LOTTIE H For: May 19 (10K)

Form 4 PIETRANGELO MICHAEL For: May 19 (10K)